Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the publication and dissemination of new treatment guidelines for peripheral arterial disease will raise awareness and understanding of the disease among primary care physicians in the next 10 years.

"These guidelines will emphasize that peripheral arterial disease should be considered a manifestation of serious underlying atherosclerotic disease that necessitates management of cardiovascular risk factors," said Mary Argent-Katwala, Ph.D., analyst at Decision Resources. "This revised approach to peripheral arterial disease will be a primary driver of increased drug use in this patient population."

The new Pharmacor study entitled Peripheral Arterial Disease also finds that, although the gold-standard method of diagnosing the disease is simple and accurate, few primary care physicians use it.

About Peripheral Arterial Disease

For many years, peripheral arterial disease has been an unheeded herald of cardiovascular diseases. Patients have had to make do with hand-me-down drugs that were originally developed for other indications. Compounding the problem is that fact that these agents provide inadequate symptomatic relief in early- stage peripheral arterial disease, and options are few-apart from surgery-in the advance stages of the disease. However, the growing recognition that peripheral arterial disease affects both life and limb is fueling pharmaceutical companies' interest in this long-neglected indication.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Despite Lack of Diagnostic Criteria and Regulatory Approval, Sales of Drugs Used to Treat Minor Depression Exceeded $2 Billion in 2003

View Now